FDA Clearance Tracker · P160048-S012
EVERSENSE CONTINUOUS GLUCOSE MONITORING SYSTEM
Last checked: Nov 20, 2026Latest source record: Nov 25, 2019 (this decision)Source: openFDAMethods & limitations
Decided
Nov 25, 2019
Approved
Time to decision
145 days
Received Jul 3, 2019. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track No User Fee
Device class
Class III
The decision
- FDA number
- P160048-S012
- Device name
- EVERSENSE CONTINUOUS GLUCOSE MONITORING SYSTEM
- Applicant
- Senseonics, Incorporated
- Applicant location
- Germantown, MD
- Received
- Jul 3, 2019
- Decided
- Nov 25, 2019
- Decision
- Approved
- Supplement type
- Normal 180 Day Track No User Fee
- Reason for supplement
- Postapproval Study Protocol
- Original approval
- P160048
Device type
- Device class
- Class III
FDA's approval statement
As written in FDA's record.
Approval of the protocol for the post-approval study (PAS) referenced above. The PAS protocol has been submitted to comply with the conditions of approval outlined in our approval order for P160048/S006
Source documents
Other decisions for Senseonics, Incorporated
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K241335 · Decided Sep 16, 2024 · 126 days after receipt
Device type: Integrated Continuous Glucose Monitoring System With Sensor Containing Dexamethasone Acetate (SBA) · Laboratory Medicine & Pathology
5 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.